Skip to main content

Table 1 Population difference and MAIC results

From: Cost-effectiveness of edaravone dexborneol versus human urinary kallidinogenase for acute ischemic stroke in China

 

Before MAIC

After MAIC

HUK

EDB

HUK

EDB

Age, year; Median

62.00

62.96

62.00

61.47

Men, %

68.05

67.45

68.05

68.05

Body mass index, kg/m2; Median

24.01

24.20

24.01

24.05

Smoke, %

43.30

38.90

43.30

43.30

Time to treatment, h; Median

30.5

28.0a

30.50

30.47

Previous stroke, %

27.12

29.05

27.12

27.12

Baseline mRS(0–1), %

92.06

99.83

92.06

92.06

NIHSS scoreb, Median

7.00

6.00

7.00

6.63

Cardioembolic, %

0.75

5.18

0.75

0.75

Hypertension, %

66.31

65.11

66.31

66.31

Diabetes, %

30.53

25.21

30.53

30.53

Hyperlipidemia, %

14.89

7.35

14.89

14.89

Coronary heart disease, %

11.20

8.68a

11.20

11.20

  1. EDB Edaravone dexborneol, HUK Human urinary kallidinogenase, mRS modified Rankin Scale, MAIC Matching-adjusted indirect comparison, NIHSS National Institutes of Health Stroke Scale
  2. aTime to treatment and proportion of coronary heart disease of EDB group were extracted from the clinical study report
  3. bThe higher NIHSS score indicates more disease severity